Bora Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St · 03/11 07:51

Bora Pharmaceuticals (TWSE:6472) Full Year 2024 Results

Key Financial Results

  • Revenue: NT$19.2b (up 36% from FY 2023).
  • Net income: NT$3.94b (up 30% from FY 2023).
  • Profit margin: 21% (in line with FY 2023).
  • EPS: NT$38.69 (up from NT$30.20 in FY 2023).
earnings-and-revenue-growth
TWSE:6472 Earnings and Revenue Growth March 11th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bora Pharmaceuticals EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 47% growth forecast for the Pharmaceuticals industry in Taiwan.

Performance of the Taiwanese Pharmaceuticals industry.

The company's shares are down 13% from a week ago.

Valuation

Our analysis of Bora Pharmaceuticals based on 6 different valuation metrics shows it might be undervalued. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.